Search company, investor...

Diasome Pharmaceuticals

Founded Year



Unattributed | Alive

Total Raised


Last Raised

$16.72M | 3 mos ago

About Diasome Pharmaceuticals

Diasome Pharmaceuticals develops hepatocyte directed vesicle technology, an insulin additive, to lessen the instances of high and low blood sugar levels in people with diabetes to improve disease management and quality of life. The company was founded in 2004 and is based in Cleveland, Ohio.

Headquarters Location

10000 Cedar Avenue Suite 6

Cleveland, Ohio, 44106,

United States


Missing: Diasome Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Diasome Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Research containing Diasome Pharmaceuticals

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Diasome Pharmaceuticals in 1 CB Insights research brief, most recently on Oct 28, 2022.

Expert Collections containing Diasome Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Diasome Pharmaceuticals is included in 2 Expert Collections, including Biopharma Tech.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.



2,046 items

Diasome Pharmaceuticals Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Diasome Pharmaceuticals Rank

Diasome Pharmaceuticals Frequently Asked Questions (FAQ)

  • When was Diasome Pharmaceuticals founded?

    Diasome Pharmaceuticals was founded in 2004.

  • Where is Diasome Pharmaceuticals's headquarters?

    Diasome Pharmaceuticals's headquarters is located at 10000 Cedar Avenue, Cleveland.

  • What is Diasome Pharmaceuticals's latest funding round?

    Diasome Pharmaceuticals's latest funding round is Unattributed.

  • How much did Diasome Pharmaceuticals raise?

    Diasome Pharmaceuticals raised a total of $80.79M.

  • Who are the investors of Diasome Pharmaceuticals?

    Investors of Diasome Pharmaceuticals include Flare Capital Partners, JDRF T1D Fund, McDonald Partners, Medicxi Ventures, Black Beret Life Sciences and 5 more.

  • Who are Diasome Pharmaceuticals's competitors?

    Competitors of Diasome Pharmaceuticals include Adastra Pharmaceuticals, Intarcia Therapeutics, Rigel Pharmaceuticals, Amylin Pharmaceuticals, Tioga Pharmaceuticals and 12 more.

Compare Diasome Pharmaceuticals to Competitors


Xenome focuses on the discovery and development of peptide pharmaceuticals based on libraries of venom and related peptides.

Alinea Pharmaceuticals

Alinea Pharmaceuticals, Inc. offers pharmaceuticals for diabetes and related metabolic disorders

Hormos Medical

Hormos Medical, A Subsidiary Of Quatrx Pharmaceuticals, Focuses On Developing Therapies For Endocrine, Metabolic And Cardiovascular Diseases.

Intarcia Therapeutics

Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.

Actinobac Biomed

Actinobac Biomed is a biopharmaceutical company developing therapeutics for multiple indications, including blood cancers, autoimmune/inflammatory diseases, and HIV. Its drug candidates are based upon Leukothera (LtxA), a natural protein that targets and eliminates white blood cells (WBCs) involved in the mechanism of many diseases. Products based upon Leukothera are being developed by Actinobac for the treatment of leukemia/lymphoma, dry eye, and psoriasis.

Inagen Aps

Inagen was formed in 2007 to develop therapies for viral diseases. The company's primary candidate is treatment for Cytomegalovirus (CMV). There is a great unmet need for effective treatment to eradicate this serious disease.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.